Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 300.00
Bid: 298.50
Ask: 301.50
Change: 13.00 (4.53%)
Spread: 3.00 (1.005%)
Open: 280.50
High: 304.50
Low: 280.50
Prev. Close: 287.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS: Deutsche raises GSK; HSBC cuts BP to Hold

Thu, 24th Jun 2021 09:49

(Alliance News) - The following London-listed shares received analyst recommendations Thursday and Wednesday:

----------

FTSE 100

----------

DEUTSCHE BANK RAISES GLAXOSMITHKLINE TO 'HOLD' (SELL) - PRICE TARGET 1,350 (1,300) PENCE

----------

CREDIT SUISSE RAISES GLAXOSMITHKLINE PRICE TARGET TO 1,400 (1,300) PENCE - 'UNDERPERFORM'

----------

UBS RAISES SAINSBURY PRICE TARGET TO 290 (275) PENCE - 'BUY'

----------

BOFA RAISES DIAGEO PRICE TARGET TO 4,150 (3,900) PENCE - 'BUY'

----------

BERENBERG RAISES CRODA INTERNATIONAL PRICE TARGET TO 7,800 (7,400) PENCE - 'BUY'

----------

BERENBERG INITIATES PHOENIX GROUP WITH 'HOLD' - TARGET 790 PENCE

----------

CREDIT SUISSE RAISES NATWEST PRICE TARGET TO 260 (247) PENCE - 'OUTPERFORM'

----------

UBS RAISES BERKELEY GROUP PRICE TARGET TO 5,400 (5,240) PENCE - 'BUY'

----------

JEFFERIES CUTS CRH PRICE TARGET TO 4,449 (4,549) PENCE - 'BUY'

----------

CREDIT SUISSE RAISES DS SMITH PRICE TARGET TO 470 (450) PENCE - 'NEUTRAL'

----------

HSBC CUTS BP TO 'HOLD' (BUY) - PRICE TARGET 360 (365) PENCE

----------

CREDIT SUISSE CUTS SEVERN TRENT PRICE TARGET TO 2,310 (2,340) PENCE - 'NEUTRAL'

----------

FTSE 250

----------

HSBC RAISES IMI TO 'BUY' ('HOLD') - TARGET 2,065 (1,370) PENCE

----------

JPMORGAN CUTS WOOD GROUP PRICE TARGET TO 340 (350) PENCE - 'OVERWEIGHT'

----------

BERENBERG RAISES TRAVIS PERKINS PRICE TARGET TO 2050 (1910) PENCE - 'BUY'

----------

BERNSTEIN RAISES ROYAL MAIL PRICE TARGET TO 650 (575) PENCE - 'MARKET-PERFORM'

----------

BERENBERG INITIATES BEAZLEY WITH 'HOLD' - TARGET 410 PENCE

----------

BERENBERG RAISES CINEWORLD GROUP PRICE TARGET TO 85 (70) PENCE - 'HOLD'

----------

BARCLAYS RAISES WORKSPACE GROUP PRICE TARGET TO 745 (700) PENCE - 'UNDERWEIGHT'

----------

JEFFERIES RAISES OXFORD BIOMEDICA PRICE TARGET TO 1,180 (950) PENCE - 'HOLD'

----------

OTHER MAIN MARKET AND AIM

----------

BERENBERG RAISES NEXT FIFTEEN COMMUNICATIONS TARGET TO 1,140 (940) PENCE - 'BUY'

----------

JEFFERIES RAISES KERRY GROUP PRICE TARGET TO 130 (127) EUR - 'BUY'

----------

RBC RAISES SMART METERING PRICE TARGET TO 1,060 (950) PENCE - 'OUTPERFORM'

----------

BERENBERG RAISES VICTORIA PRICE TARGET TO 1,110 (1,050) PENCE - 'BUY'

----------

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
17 Jan 2022 09:32

Oxford Biomedica starts search for new CEO as Dawson steps down

Oxford Biomedica starts search for new CEO as Dawson steps down

Read more
17 Jan 2022 07:10

Oxford Biomedica CEO John Dawson to step down

(Sharecast News) - Oxford Biomedica chief executive John Dawson said he was stepping down after 13 years at the helm of the Gene and cell therapy firm which helped develop a Covid-19 vaccine with AstraZeneca.

Read more
5 Jan 2022 08:54

Oxford Biomedica wins new agreement for LentiVector platform

Oxford Biomedica wins new agreement for LentiVector platform

Read more
5 Jan 2022 07:29

Oxford Biomedica signs licence, supply deal with Cabaletta Bio

(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.

Read more
15 Dec 2021 09:33

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

Read more
13 Dec 2021 10:03

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Read more
13 Dec 2021 07:31

Oxford Biomedica strikes new license and supply agreements

(Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck new license and supply agreements for its lentiviral vectors.

Read more
19 Oct 2021 10:50

Oxford BioMedica licences technology for cystic fibrosis treatment

Oxford BioMedica licences technology for cystic fibrosis treatment

Read more
19 Oct 2021 09:18

Boehringer Ingelheim licenses Oxford Biomedica's lentiviral vector technology

(Sharecast News) - Gene and cell therapy firm Oxford Biomedica said on Tuesday that pharmaceutical giant Boehringer Ingelheim had exercised its option to license its lentiviral vector technology to manufacture, register and commercialise a treatment for cystic fibrosis.

Read more
30 Sep 2021 09:35

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

Read more
28 Sep 2021 09:40

LONDON BROKER RATINGS: Investec prefers 888 over Entain

LONDON BROKER RATINGS: Investec prefers 888 over Entain

Read more
22 Sep 2021 16:54

LONDON MARKET CLOSE: Stocks up as Evergrande fears soothed before Fed

LONDON MARKET CLOSE: Stocks up as Evergrande fears soothed before Fed

Read more
22 Sep 2021 09:16

TOP NEWS: Oxford BioMedica sales double; Serum Institute buys stake

TOP NEWS: Oxford BioMedica sales double; Serum Institute buys stake

Read more
22 Sep 2021 07:03

Oxford Biomedica swings to profit on Covid-19 vaccine sales

(Sharecast News) - Covid-19 vaccine producer Oxford Biomedica swung to a profit in the half year on the back of a surge in revenues through its partnership deal with AstraZeneca and announced that Serum Institute of India has agreed to invest £50m in the group in return for a 3.9% stake in the company.

Read more
22 Sep 2021 07:03

Oxford Biomedica swings to profit on Covid-19 vaccine sales

(Sharecast News) - Covid-19 vaccine producer Oxford Biomedica swung to a profit in the half year on the back of a surge in revenues through its partnership deal with AstraZeneca and announced that Serum Institute of India has agreed to invest £50m in the group in return for a 3.9% stake in the company.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.